Sign in
CompletedNo phase

Perioperative Salivary Alpha-amylase as a Predictor of Delirium After Lower Extremity Vascular Bypass Surgery

Key facts

Who runs it
Tanta University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
60 people enrolled
Started
10 Feb 2024
Ended
19 Jun 2025
Type of study
Observational, 2 groups
Treatments tested
  • Salivary Alpha-amylase
Record updated
25 June 2025

Who can take part

Age
65 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Age ≥ 65 years
  • Both sexes
  • American Society of Anesthesiologists (ASA) physical status III
  • Undergoing lower extremity vascular surgery under general anesthesia

Who cannot take part

  • Patients who used any medication that could affect salivary glands (such as antihypertensive, antidepressants or antipsychotic drugs)
  • History of psychiatric diseases or previous stroke
  • Previous history of pod
  • Inability to communicate
  • Those with smoking and drinking habits
  • Pregnant female

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of this study is to evaluate the role of salivary Alpha-amylase as a predictor biomarker of POD in elderly patients undergoing limb bypass surgery.

The 2 groups in the trial

  • Postoperative delirium (POD) group

    Patients who will develop postoperative delirium

    Treatment: Salivary Alpha-amylase

  • No Postoperative delirium (POD) group

    Patients who will not develop postoperative delirium

    Treatment: Salivary Alpha-amylase

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
25 June 2025